reports
QuickView: Focused on HIV immunotherapy and Ebola
GeoVax continues to focus on advancing both its HIV immunotherapy programme and Ebola vaccines, which will require additional funding. Further development of the GOVX-B11 preventative HIV vaccine remains under consideration by the US NIH, although a large Phase IIb trial in 2015 now seems unlikely as HVTN reconsiders the merits of adding a protein boost. The exercise of certain warrants has increased cash to c $1.7m.
QuickView: Leveraging technology for Ebola
GeoVax has announced plans to develop two Ebola vaccines, one for the strain responsible for the current outbreak and a preventative vaccine against multiple strains for the future. GeoVax plans to construct the MVA vectors using its recombinant MVA vaccine platform ready for preclinical testing, for which additional funds are likely to be needed. These could potentially come from government sources, or from the capital markets.
QuickView: Q314 NIH funding decision could be key
GeoVax provided an update on its lead programmes with the recent Q214 financial results. The next development steps for GOVX-B11 are subject to US NIH funding and a decision, expected in Q314, to fund production of a key component of the vaccine for further trials could be indicative of future support. GeoVax is also working on the elements required for an HIV immunotherapy, with a Phase I/II trial currently being planned.
QuickView: Valneva vaccine deal
An agreement has been signed granting rights to Valneva’s EB66 cell line for clinical and commercial production of the MVA component of GeoVax’s preclinical clade C HIV vaccines for the developing world. This will allow for manufacturing of the vaccine for first clinical trials by a CMO (contract manufacturing organisation). The priority remains the lead prophylactic vaccine GOVX-B11 for the developed world, where a Phase IIb trial is being planned with the HIV Vaccine Trials Network (HVTN).
QuickView: Prophylactic potential
GeoVax continues to work with the HIV Vaccine Trials Network (HVTN) to progress development of its lead GOVX-B11 prophylactic HIV vaccine. To date HVTN has conducted both Phase I and most recently Phase IIa development at an estimated cost of $10m, supported by US NIH funding. A planning meeting with HVTN recently took place and continued collaboration, in the absence of alternative funding, will be key to securing the future development of GOVX-B11.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.